沙利度胺在既往未经治疗的多发性骨髓瘤患者中的作用。

Role of thalidomide in previously untreated patients with multiple myeloma.

作者信息

Musto Pellegrino, D'Auria Fiorella, Pietrantuono Giuseppe, Bringhen Sara, Morabito Fortunato, Di Raimondo Francesco, Pozzi Samantha, Sacchi Stefano, Boccadoro Mario, Palumbo Antonio

机构信息

Unit of Hematology and Stem Cell Transplantation, IRCCS-CROB, Oncology Referral Center of Basilicata, Rionero in Vulture, Pz, Italy.

出版信息

Expert Rev Anticancer Ther. 2008 Oct;8(10):1569-80. doi: 10.1586/14737140.8.10.1569.

DOI:10.1586/14737140.8.10.1569

PMID:18925849

Abstract

Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years. Despite some toxicities, it has demonstrated significant efficacy in elderly patients, as well as in the setting of younger subjects receiving autologous stem cell transplantation. Here, we report and discuss the clinical results achieved with thalidomide alone or in combination with dexamethasone or other drugs, such as melphalan, cyclophosphamide, doxorubicin and bortezomib, in previously untreated myeloma patients.

摘要

沙利度胺是过去10年中多发性骨髓瘤患者最重要的治疗进展之一。尽管存在一些毒性，但它已在老年患者以及接受自体干细胞移植的年轻患者中显示出显著疗效。在此，我们报告并讨论了在既往未治疗的骨髓瘤患者中单独使用沙利度胺或与地塞米松或其他药物（如美法仑、环磷酰胺、阿霉素和硼替佐米）联合使用所取得的临床结果。